APH02174 | APH02174 : Degrader (PROTAC) of IRAK4
RATINGS:
Cellular Use: (1 reviews)

In Model Organisms: (1 reviews)
Control Compounds
Vendors

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
IRAK4
    • DC50:4.01 nM
    • Dmax:94%
    • IC50:16.43 nM
    Degrader (PROTAC)
    up to 100 nM

    Selectivity

    In Cell Selectivity Assessment
    Potency Assay Off-Target:
    The degradative selectivity of APH02174 was evaluated using tandem mass tag-based global discovery p ...
    In Cell Selectivity Assessment
    Potency Assay Off-Target:
    To determine whether APH02174 can degrade the transcription factor SALL4 and Zn-finger proteins (IKZ ...

    Potency
    Cellular
    In Vitro

    IRAK4

    Mode of Action: Degrader (PROTAC)

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    In Vivo Validations

    Mouse
    Dose: 2 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 3.78 ± 0.09 h
    Systemic clearance: 0.880 ± 0.07 mL/min/Kg
    Cmax: 1867 ± 306 ng/mL
    Area Under the Curve:: 11671 ± 1196 h*ng/mL
    Volume of Distribution at Steady-State: 1.66 ± 0.22 L/Kg

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Dose: 10 mg/Kg
    Route of delivery: Oral
    Plasma half life: 4.34 ± 0.15 h
    Cmax: 2073 ± 235 ng/mL
    Tmax: 2.67 ± 1.15 h
    Area Under the Curve:: 23388 ± 2557 h*ng/mL
    Bioavailability: 45 ± 5%

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Rat
    Dose: 2 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 4.00 ± 0.10 h
    Systemic clearance: 12.8 ± 0.85 mL/min/Kg
    Cmax: 1420 ± 157 ng/mL
    Area Under the Curve:: 2589 ± 166 h*ng/mL
    Volume of Distribution at Steady-State: 2.66 ± 0.13 L/Kg

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Dose: 30 mg/Kg
    Route of delivery: Oral
    Plasma half life: 3.43 ± 0.10 h
    Cmax: 613 ± 190 ng/mL
    Tmax: 6.00 h
    Area Under the Curve:: 7093 ± 1072 h*ng/mL
    Bioavailability: 18 ± 3%

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Dog
    Dose: 1 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 8.10 ± 0.84 h
    Systemic clearance: 4.75 ± 1.41 mL/min/Kg
    Cmax: 599 ± 87 ng/mL
    Area Under the Curve:: 3669 ± 1082 h*ng/mL
    Volume of Distribution at Steady-State: 2.73 ± 0.54 L/Kg

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Dose: 5 mg/Kg
    Route of delivery: Oral
    Plasma half life: 10.6 ± 2.29 h
    Cmax: 360 ± 122 ng/mL
    Tmax: 4.00 h
    Area Under the Curve:: 6994 ± 2214 h*ng/mL
    Bioavailability: 39 ± 12%

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Monkey (Cynomolgus)
    Dose: 1 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 8.67 ± 0.46 h
    Systemic clearance: 9.20 ± 1.70 mL/min/Kg
    Cmax: 672 ± 95 ng/Kg
    Area Under the Curve:: 1818 ± 299 h*ng/mL
    Volume of Distribution at Steady-State: 3.85 ± 0.44 L/Kg

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Dose: 20 mg/Kg
    Route of delivery: Oral
    Plasma half life: 9.07 ± 0.99 h
    Cmax: 229 ± 33 ng/mL
    Tmax: 6.00 h
    Area Under the Curve:: 3997 ± 461 h*ng/mL
    Bioavailability: 11 ± 1%

    DOI Reference: 10.1021/acs.jmedchem.5c00711

    Chemical Information

    Molecular Formula C49H55N7O8
    SMILEs Cn1c(=O)n(C2CCC(=O)NC2=O)c2cccc(C#CCO[C@H]3CC[C@H](CN4CCC5(CC4)Cc4cc(NC(=O)c6coc7cccnc67)c(N6CCC(CO)CC6)cc4O5)CC3)c21
    InChI InChI=1S/C49H55N7O8/c1-53-45-33(5-2-7-38(45)56(48(53)61)39-13-14-43(58)52-47(39)60)6-4-24-62-35-11-9-31(10-12-35)28-54-22-17-49(18-23-54)27-34-25-37(51-46(59)36-30-63-41-8-3-19-50-44(36)41)40(26-42(34)64-49)55-20-15-32(29-57)16-21-55/h2-3,5,7-8,19,25-26,30-32,35,39,57H,9-18,20-24,27-29H2,1H3,(H,51,59)(H,52,58,60)/t31-,35-,39?
    Molecular weight 869.41 Da
    AlogP 5.316500000000007
    HBond acceptors 15
    HBond donors 3
    Atoms 119

    References

    Cross References

    Expert Reviews


    (on 6 Feb 2026 )
    Cellular Use Rating
    In Model Organisms
    This is a potent degrader of IRAK4 as determined by HiBiT-IRAK4 assays in THP1cells, as well as by Western blot in human and mouse PBMCs. Degradation selectivity characterised by global proteomics showed...
    Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria